Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMinakshi Guha

Discussion

Loading...

Member takes

Overview

Pilot study demonstrates high concordance of NGS-based MRD detection in blood and bone marrow in AML, suggesting improved clinical monitoring.

Key Points

  • High concordance of MRD status between matched blood and bone marrow samples was observed with 83.8% for Assay A and 86% for Assay B.
  • Next-generation sequencing assays showed a higher MRD positivity rate for Assay A (57%) compared to Assay B (33%).
  • Longitudinal analysis indicated stable MRD status for most patients, while some displayed dynamic changes in variant allele frequency over time.
  • Significant differences in assay sensitivity and genetic mutations detected highlight the need for standardized MRD definitions and improved validation.

Cite This Study

Minakshi Guha (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d553https://doi.org/10.1182/blood-2025-7044
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  2. 2Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia2025 · 5 citations
  3. 3MRD-seq: A sensitive next generation sequencing-based approach for measurable residual disease detection in acute myeloid leukaemia2025
  4. 4Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients2025
  5. 5Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025